All In Biotech

Drug Trial Radar · NCT02752191

Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

Last checked: Nov 20, 2026Latest source record: Dec 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

17

Actual

Start

Apr 2016

Primary completion

Dec 19, 2018

Study completion Dec 19, 2018

Sponsor

Lead sponsor
Paul FinnAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 1 day, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The standard clinical cardiovascular MRI practice for children with CHD frequently involves the use of gadolinium-based contrast agents (GBCA) to enhance tissue contrast. Most GBCAs are small molecules that quickly cross the capillary wall and access the interstitial space, a process which diminishes the signal contrast between blood vessels and surrounding tissue. Therefore, these types of GBCA are most useful for first-pass MR angiography, wherein the images are acquired quickly during the initial 15-30 seconds post-injection when the GBCA concentration is much higher in the arteries than in the interstitial space. For young children with complex CHD, the stringent requirements for high spatial resolution, and the need for cardiac gating and good blood-myocardium contrast in order to provide detailed evaluation of intracardiac structures are not compatible with conventional GBCA-based first-pass MR angiography. Even with Ablavar® (gadofosveset trisodium), an FDA approved GBCA with longer intravascular half-life than other GBCAs, cardiac-gated Ablavar®-enhanced MRI may be insufficient for young children with CHD based on our institutional experience and on data from the literature; there remains diminished blood-tissue contrast during the high-resolution cardiac-gated MRI. Furthermore, there have been safety concerns regarding gadolinium deposition in brain tissues after repeated GBCA exposure as well as concerns of nephrogenic systemic fibrosis (NSF) associated with GBCA injection in young children \< 2 years old who may have immature renal function. The long-term health consequences of these effects in the pediatric population are unclear. For the above reasons, we seek to study the diagnostic imaging effectiveness of Feraheme (Feraheme®), an FDA-approved drug for parenteral iron supplementation, as an MRI contrast agent in children with CHD. Although Feraheme® has been approved for the treatment of iron deficiency anemia secondary to renal disease, Feraheme® has been used as an off-label MRI contrast agent at select medical centers.

Conditions

  • Pediatric Congenital Heart Disease

Interventions

  • ferumoxytolDrug

    ferumoxytol as an MRI contrast agent infused over several minutes

  • gadofosvesetDrug

    gadofosveset as an MRI contrast agent injected over several seconds

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Image Quality Score Among 7 Anatomical Structures.Time frame: day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.